<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603745</url>
  </required_header>
  <id_info>
    <org_study_id>zoely1984</org_study_id>
    <nct_id>NCT01603745</nct_id>
  </id_info>
  <brief_title>Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is often associated with pathological conditions, such as
      insulin resistance (IR), type 2 diabetes (DM2), obesity and it has potentially increased risk
      for cardiovascular disease (CVD). Of note, risk factors for CVD including dyslipidaemia,
      hypertension, oxidative stress and inflammation are associated with PCOS. The investigators
      want to evaluate the effects of two different types of E/P therapy on cardiovascular risk in
      PCOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PCOS is the most common female endocrinopathy in reproductive age. This syndrome is a
      heterogeneous condition characterized by several symptoms and clinical signs related to
      reproductive, cardiometabolic and psychological disorders.We recently demonstrated that young
      PCOS women show an expansion of an unusual T-cell population with proinflammatory functions,
      identified by CD4+CD28null T lymphocytes . Of note, this T subpopulation has been found to be
      expanded in patients with unstable angina, type 2 diabetes (DM2), in absence of clinical
      evidence of CVD 12, and has been recently associated to recurrent coronary instability .Based
      on the above mentioned evidences, the aim of the present study is to evaluate the effects of
      DRPS/EE alone versus metformin alone versus DRPS/EE plus metformin on the CD4+CD28null T
      cells frequency and on endocrino-metabolic parameters, in hyperinsulinemic PCOS patientsTo
      evaluate long-term effects of drospirenone (DRSP)/ethinylestradiol (EE) and NOMAC-valerate
      estardiol on some cardiovascular risk factors in PCOS patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular risk</measure>
    <time_frame>120 minutes</time_frame>
    <description>total testosterone (T), SHBG, androstenedione (A), 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone sulphate (DHEAS), triglycerides, total cholesterol, high- and low-density lipoprotein cholesterol (HDL and LDL cholesterol) and alanine aminotransferase (ALT),CD4+CD28null frequency</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>NOMAC-valerate estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>E/P therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drospirenone/ethinylestradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>E/P therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoely</intervention_name>
    <description>1 pill every day</description>
    <arm_group_label>NOMAC-valerate estradiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yasmin</intervention_name>
    <description>1 pill every day</description>
    <arm_group_label>Drospirenone/ethinylestradiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with PCOS aged 18-35 years

        Exclusion Criteria:

          -  chronic or acute inflammatory disease

          -  cancer

          -  autoimmune disease

          -  treatment with clomiphene citrate

          -  antiandrogens

          -  drugs to control appetite or insulin-sensitizing drugs (metformin, pioglitazone and
             rosiglitazone) during the last 6 months prior to our evaluation, DM2, hypertension,
             major surgery in the last 3 months or other hormonal dysfunctions (hypothalamic,
             pituitary, thyroidal, or adrenal causes)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic university of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosanna Apa, MD</last_name>
      <email>sandrina84@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Rosanna Apa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Niccoli G, Apa R, Lanzone A, Liuzzo G, Spaziani C, Sagnella F, Cosentino N, Moro F, Martinez D, Morciano A, Bac√† M, Pazzano V, Gangale MF, Tropea A, Crea F. CD4+CD28 null T lymphocytes are expanded in young women with polycystic ovary syndrome. Fertil Steril. 2011 Jun 30;95(8):2651-4. doi: 10.1016/j.fertnstert.2011.01.129. Epub 2011 Feb 16.</citation>
    <PMID>21324454</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2012</study_first_posted>
  <last_update_submitted>May 21, 2012</last_update_submitted>
  <last_update_submitted_qc>May 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Rosanna Apa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

